Skip to main content
PepStack
Hormone · Profile

Progesterone

P4 · Prometrium · Utrogestan · Crinone

Sex Hormones & TRTApproved
MW
314.5g/mol
Formula
C21H30O2

Progesterone (P4) is a steroid hormone primarily produced by the corpus luteum in the ovaries and plays a vital role in the menstrual cycle and pregnancy. Researchers primarily study progesterone for its critical functions in reproductive health, particularly its influence on uterine receptivity and the maintenance of pregnancy. Key findings indicate that progesterone signaling is essential for successful embryo implantation, with transcription factors like WT1 identified as crucial partners in mediating its effects in uterine cells. Additionally, studies suggest that fluctuations in progesterone levels during menopause can exacerbate conditions such as migraines, highlighting its broader implications in women's health. Current research continues to explore the molecular mechanisms of progesterone action and its potential therapeutic applications in hormone replacement therapy and reproductive health management.

Overview

Übersicht

Progesterone (P4), also known as Prometrium or Utrogestan, is a naturally occurring steroid hormone produced primarily in the ovaries, placenta, and adrenal glands. It belongs to the class of sex hormones and is a key component of the reproductive system. As an endogenous hormone, it plays a vital role in the menstrual cycle and pregnancy. Synthetic forms of progesterone are used in various hormonal therapies. Researchers have extensively studied progesterone's role in reproductive health, particularly its involvement in preparing the uterus for embryo implantation and maintaining pregnancy. Additionally, its role in hormone replacement therapy (HRT) during menopause has been a significant area of research. Progesterone acts primarily through the progesterone receptor (PR), which is a nuclear receptor that regulates gene expression. It is involved in various biological pathways, including those that prepare the endometrium for implantation and modulate immune responses during pregnancy. The hormone's interaction with other transcription factors, such as WT1, is crucial for its function in uterine receptivity. Pharmacokinetically, progesterone has a short circulating half-life, and its bioavailability varies significantly with the route of administration. Oral progesterone has poor bioavailability due to first-pass metabolism, while micronized formulations improve absorption. Progesterone is used clinically in hormone replacement therapy, particularly in postmenopausal women, to mitigate menopausal symptoms and protect the endometrium when used with estrogen. It is regulated as a prescription medication in many countries.

Chemical profile

Chemische Struktur

Chemical structure of Progesterone
FormelC21H30O2
Molekulargewicht314.5g/mol
CAS-Nummer57-83-0
PubChem CID5994
Mechanism

Wirkmechanismus

Progesterone acts on the progesterone receptor (PR), a nuclear receptor that modulates gene expression by binding to specific DNA sequences. This interaction influences various biological processes, including uterine receptivity and immune modulation during pregnancy.

Mechanism

Signalweg

Progesterone exerts its effects primarily through binding to the progesterone receptor (PR), which then interacts with transcription factors such as WT1 to facilitate PR-chromatin binding and activate target gene transcription essential for uterine receptivity during implantation. This signaling involves the regulation of gene expression that supports processes like decidualization and maintenance of pregnancy, although the complete molecular mechanisms and pathways involved in PR-mediated signaling remain to be fully elucidated. Additionally, progesterone's role in modulating inflammation and parturition is influenced by enzymes like aldo-keto reductase family 1 member C1 (AKR1C1), which can inactivate progesterone in decidual stromal cells, highlighting its complex regulatory functions in reproductive biology.

Half-Life & Pharmacokinetics

ENEndogenous

Circulating half-life ~5 minutes

POOral

Poor bioavailability due to first-pass metabolism

Micronized formulations improve oral bioavailability; pharmacokinetics can vary with formulation.

Storage

Temperature

Store at room temperature (15-30C)

Light

Protect from light

Form

Capsules stable for 2+ years

Notes

Keep in original packaging to protect from moisture.

Solubility

Löslichkeit

Progesterone is poorly soluble in water but soluble in ethanol and oils.

Legal Status

🇩🇪DE

Verschreibungspflichtig (prescription only); not a controlled substance under BtMG.

🇺🇸US

FDA approved for certain uses; prescription required.

🇦🇺AU

TGA Schedule 4 (prescription only medicine).

🇬🇧UK

Prescription only medicine (POM) under MHRA regulation.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Open Questions

Offene Forschungsfragen

Current evidence is limited regarding the detailed molecular mechanisms underlying progesterone receptor-chromatin binding and transcriptional activity in the uterus, particularly in relation to the role of WT1 and other potential co-factors. Further research is needed to explore the long-term effects of hormone replacement therapy combining estrogen and progesterone on migraine exacerbation in diverse populations, particularly focusing on women with varying histories of menstrual migraines. Additionally, larger randomized controlled trials are necessary to investigate the therapeutic potential of inhibiting AKR1C1 in the context of inflammation-induced preterm labor, as well as to assess the implications of progesterone in various metabolic and cognitive outcomes in menopausal women.

189 Research Publications

2,894

Total Citations

41

Human/RCT

3.0

Avg. Influence

2025

Latest

Sort
Filter
#01

Influence of progesterone on oocyte quality and embryo development in cows.

ReviewInfluence12.0
242
The study demonstrated that progesterone influences oocyte quality and embryo development in cattle, with implications for early embryo loss during pregnancy.
#02

Physiological and practical effects of progesterone on reproduction in dairy cattle.

ReviewInfluence12.0
238
The study demonstrated that manipulating progesterone levels in dairy cattle can improve reproductive success, particularly during timed artificial insemination protocols.
#03

Progesterone-Related Immune Modulation of Pregnancy and Labor.

ReviewInfluence7.0
173
Researchers observed that progesterone modulates inflammation in the maternal reproductive and immune systems, playing a critical role in pregnancy maintenance and labor.
#04

Multiplicity of progesterone's actions and receptors in the mammalian ovary.

ReviewInfluence8.0
132
The study demonstrated that progesterone regulates ovarian function through multiple receptor pathways, influencing granulosa and luteal cell activity.
#05

Role of progesterone in embryo development in cattle.

ReviewInfluence3.0
97
Researchers observed that progesterone is critical for conceptus development in cattle, influencing endometrial secretions essential for early pregnancy.
#06

Novel progesterone receptors: neural localization and possible functions.

ReviewInfluence7.0
92
Researchers observed that novel progesterone receptors, particularly PGRMC1, are abundant in brain regions and may regulate various neuroendocrine functions.
#07

Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3).

HumanInfluence10.0
86
The study demonstrated that vaginal progesterone gel (Crinone) provides greater bioavailability and less variability in absorption compared to oral progesterone (Prometrium) in postmenopausal women.
#08

Progesterone for the prevention and treatment of osteoporosis in women.

ReviewInfluence2.0
81
Researchers observed that progesterone supplementation may help prevent osteoporosis in women by promoting bone formation, although further randomized controlled trials are needed.
#09

Progesterone Modulation of Pregnancy-Related Immune Responses.

Animal
78
Researchers observed that progesterone modulates immune responses during pregnancy by enhancing immune tolerance while suppressing antigen-specific T cell activation.
#10

The effects of progesterone on oocyte maturation and embryo development.

In VitroInfluence2.0
75
The study demonstrated that progesterone significantly improves mouse embryo development and survival rates, although it does not enhance in vitro maturation rates of oocytes.

Clinical Trials (182)

Preclinical
Phase I
Phase II
Phase III
Approved

182

Total Trials

46,465

Total Enrolled

The Women's Health Initiative Memory Study (The WHIMS Study)

NCT00685009COMPLETED
Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment

7,525

Started

1996

Primary outcome

All-cause dementia

Dementia Syndromes

Impact of Serum Progesterone Levels on the Day of β-hCG Test in Artificial Cycles on the Ongoing Pregnancy Rate.

NCT05750849RECRUITING
Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Enrollment

900

Started

2023

Primary outcome

LIVE BIRTH

Infertility, Female

Intramuscular vs Rectal Progesterone in Preventing Preterm Labour After Cervical Cerclage

NCT07307092COMPLETED
Sponsor

Hina Mukhtar

Enrollment

820

Started

2021

Primary outcome

Frequency of Preterm Birth (<37 Weeks)

Preterm LabourCervical InsufficiencyPregnancy, High-Risk

Pessary Versus Progesterone in Singletons

Sponsor

Mỹ Đức Hospital

Enrollment

804

Started

2020

Primary outcome

Rate of preterm birth <37 weeks of gestation by any cause

Preterm BirthShort Cervix

Impact of Serum Progesterone in Modified Natural Cycles and Stimulated Cycles on Ongoing Pregnancy Rate

NCT04259996COMPLETED
Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Enrollment

488

Started

2020

Primary outcome

Ongoing pregnancy rate

Infertility, Female

Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.

NCT04722471COMPLETED
Sponsor

Instituto Bernabeu

Enrollment

347

Started

2021

Primary outcome

Serum progesterone level

Luteal Phase Defect

Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders

Sponsor

Peking Union Medical College Hospital

Enrollment

330

Started

2022

Primary outcome

Menstrual improvement

Menstrual Disorders

Cerclage With Progesterone Versus Progesterone Only in Singleton Pregnancies

NCT06463652RECRUITING
Sponsor

Mỹ Đức Hospital

Enrollment

328

Started

2024

Primary outcome

Time from randomization to delivery

Preterm BirthShort Cervix

Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies

NCT02623881COMPLETED
Sponsor

Vietnam National University

Enrollment

300

Started

2016

Primary outcome

Preterm birth before 34 weeks of gestation

Pregnancy

Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate

NCT01046708COMPLETED
Sponsor

Universitair Ziekenhuis Brussel

Enrollment

300

Started

2008

Primary outcome

ongoing pregnancy rate

Infertility

Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

NCT05767086COMPLETED
Sponsor

Bezmialem Vakif University

Enrollment

297

Started

2023

Primary outcome

Rate of clinical pregnancy

Infertility

Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women

NCT04531943COMPLETED
Sponsor

Emory University

Enrollment

285

Started

2020

Primary outcome

Percent of Rectal Mucosal Cluster of Differentiation 4 (CD4+) T Cells Expressing C-C Chemokine Receptor Type 5 (CCR5) in Cohort 1

HIV Prevention

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

NCT00702234COMPLETED
Sponsor

Organon and Co

Enrollment

268

Started

2007

Primary outcome

Percentage of Women With Ongoing Pregnancy After a Corifollitropin Alfa COS Cycle in Base Study and ≥1 Live Born Infant During Follow-up (Live Birth Rate)

PregnancyNeonates

Pessary Versus Cerclage With or Without Progesterone in Twins

NCT03863613TERMINATED
Sponsor

Mỹ Đức Hospital

Enrollment

219

Started

2019

Primary outcome

Preterm birth <34 weeks

Preterm BirthTwin PregnancyShort Cervix

Sex Differences, Hormones & Smoking Cessation

NCT01744574COMPLETED
Sponsor

University of Minnesota

Enrollment

216

Started

2012

Primary outcome

Number of Participants With 7-day Point Prevalence Abstinence From Smoking at Week 4

Tobacco Cessation

Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patient

Sponsor

Fayoum University

Enrollment

210

Started

2023

Primary outcome

The number of oocytes retrieved per patient

Polycystic Ovary SyndromeInfertilityIVF

the Effect of Endometrial Compaction Caused by Progesterone Effect on Pregnancy Outcomes

NCT04733235COMPLETED
Sponsor

Akdeniz University

Enrollment

205

Started

2020

Primary outcome

The change in endometrial thickness

InfertilityFemale InfertilityFrozen-thawed Embryo Transfer

Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study

NCT07732348NOT_YET_RECRUITING
Sponsor

Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)

Enrollment

195

Started

2026

Primary outcome

Number of Mature (MII) Oocytes Retrieved

Infertility, FemaleOvulation Induction

Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol

Sponsor

Cairo University

Enrollment

179

Started

2013

Primary outcome

Number of the retrieved oocytes

Invitro Fertilizaion

Vaginal Progesterone Improves Clinical Outcomes of RIF Patients

Sponsor

Nanjing University

Enrollment

152

Started

2023

Primary outcome

Embryo implantation rate

Infertility, Female

GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET

NCT07642700NOT_YET_RECRUITING
Sponsor

Guoxia Yang

Enrollment

150

Started

2026

Primary outcome

Clinical pregnancy rate

Chronic Endometritis

The Use of Progesterone to Reduce Preterm Birth

NCT00830765COMPLETED
Sponsor

University of Mississippi Medical Center

Enrollment

144

Started

2004

Primary outcome

Weeks Gestation at Birth Among Patients Receiving the Active Drug.

Preterm Birth

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

Sponsor

Shaare Zedek Medical Center

Enrollment

144

Started

2022

Primary outcome

Clinical pregnancy rate

Luteal Phase Support

Role of Low Dose Injectable Progesterone in Triggering Ovulation

NCT06928844RECRUITING
Sponsor

The General Authority for Teaching Hospitals and Institutes

Enrollment

120

Started

2025

Primary outcome

Incidence of ovulation rates

Low DoseProgesteroneTriggering Ovulation

Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding

NCT04710017COMPLETED
Sponsor

Assiut University

Enrollment

110

Started

2021

Primary outcome

Number of bleeding days

Uterine Bleeding

HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness

NCT05280028RECRUITING
Sponsor

Far Eastern Memorial Hospital

Enrollment

100

Started

2022

Primary outcome

Overactive bladder symptoms

Menopausal Syndrome

Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle

NCT04846218COMPLETED
Sponsor

Ain Shams University

Enrollment

100

Started

2016

Primary outcome

Clinical pregnancy rate

Infertility, Female

The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes

Sponsor

Zekai Tahir Burak Women's Health Research and Education Hospital

Enrollment

100

Started

2014

Primary outcome

Live Birth Rate

Infertility

Vaginal Progesterone Supplementation in the Management of Preterm Labor

NCT03202836COMPLETED
Sponsor

Chulalongkorn University

Enrollment

90

Started

2017

Primary outcome

Time from preterm labor pain to delivery

Preterm Labor

Does Hormonal Luteal Support After Intra-uterine Insemination (IUI) Increase the Pregnancy Rate?

NCT00700492TERMINATED
Sponsor

University Hospital, Gasthuisberg

Enrollment

82

Started

2004

Primary outcome

clinical pregnancy rate per cycle

Subfertility

Canadian Study on the Association of Pessary With Progesterone

NCT03227705COMPLETED
Sponsor

Université de Sherbrooke

Enrollment

79

Started

2018

Primary outcome

Recruitment feasibility

Preterm BirthShort Cervix

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

NCT00016601COMPLETED
Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment

76

Started

2001

HIV Infections

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

NCT04108039COMPLETED
Sponsor

Fundacion Dexeus

Enrollment

44

Started

2019

Primary outcome

Number of euploid embryos as compared between the 2 ovarian stimulation cycles

InfertilityIVFPreimplantation Diagnosis

Sexual Intercourse and Vaginal Absorption of Progesterone

NCT05232344COMPLETED
Sponsor

University Hospital, Montpellier

Enrollment

40

Started

2022

Primary outcome

Progesterone dosage 1

Infertility

Progesterone Action on Endometrium of PCOS

NCT05062135COMPLETED
Sponsor

University of Sao Paulo General Hospital

Enrollment

36

Started

2014

Primary outcome

Endometrial biopsy

Polycystic OvaryProgesterone Resistance

Early Menopause Hormone Treatment and Cognition

NCT01046643COMPLETED
Sponsor

University of Michigan

Enrollment

30

Started

2010

Primary outcome

Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans

Menopausal Syndrome

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

NCT01381016COMPLETED
Sponsor

University of Colorado, Denver

Enrollment

30

Started

2011

Primary outcome

Luteinizing Hormone Pulse Amplitude

ObesityInfertility

Vaginal Progesterone for Prevention of Preterm Birth After an Episode of Preterm Labor

NCT01523483COMPLETED
Sponsor

University Medical Centre Ljubljana

Enrollment

30

Started

2012

Primary outcome

Preterm delivery (before completed 37th week of gestation)

Preterm Birth

PK of Depo SubQ Injected in the Upper Arm

NCT01143207COMPLETED
Sponsor

FHI 360

Enrollment

26

Started

2010

Primary outcome

Cmax (Maximal Serum Concentration of Medroxyprogesterone Acetate (MPA))

Contraception

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01427595COMPLETED
Sponsor

University of Virginia

Enrollment

25

Started

2009

Primary outcome

Change in Progesterone Sensitivity Index Before and After Metformin Treatment.

Polycystic Ovary SyndromeHyperandrogenism

Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

NCT01023178COMPLETED
Sponsor

Stanford University

Enrollment

20

Started

2007

Primary outcome

Estradiol

Ovarian Failure, Premature

Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases

NCT04665232COMPLETED
Sponsor

San Carlo Public Hospital, Potenza, Italy

Enrollment

18

Started

2014

Primary outcome

Pregnancy Rate percentage, Implantation Rate percentage, Live Birth Rate percentage

Autoimmune DiseasesInfertility

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198COMPLETED
Sponsor

University of Colorado, Denver

Enrollment

17

Started

2014

Primary outcome

Changes in Prefrontal Cortex Brain Activation at 6 Months

Cognitive ImpairmentExecutive DysfunctionEndothelial DysfunctionCardiovascular Disease

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

NCT06468215NOT_YET_RECRUITING
Sponsor

Peking University People's Hospital

Enrollment

16

Started

2024

Primary outcome

The Time Required for Complete Remission for the First Time

Carcinoma, EndometrioidFertility Preservation

Comparing Double Dose of Vaginal Progesterone to no Treatment for Prevention of Preterm Birth in Twins and Short Cervix

NCT02329535TERMINATED
Sponsor

HaEmek Medical Center, Israel

Enrollment

15

Started

2015

Primary outcome

Preterm delivery

Premature Birth

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

NCT06549855RECRUITING
Sponsor

Peking University People's Hospital

Enrollment

10

Started

2024

Primary outcome

Complete remission (CR) rate

Endometrial CancerEndometrioid CarcinomaMismatch Repair Deficiency

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NCT00676026COMPLETED
Sponsor

University of Pennsylvania

Enrollment

8

Started

2005

Primary outcome

To Determine the Impact of GABA-A Receptor Agonists (Benzodiazepines, Allopregnanolone) and Other GABA-modulating Agents (Fluoxetine) on Cortical GABA Levels by Menstrual Cycle Phase as Measured Using 1H-MRS in Healthy Controls.

Healthy

Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer

NCT06526520RECRUITING
Sponsor

ART Fertility Clinics LLC

Enrollment

5

Started

2024

Primary outcome

Relaxin measurement

Frozen Embryo Transfer

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454COMPLETED
Sponsor

Oregon Health and Science University

Enrollment

5

Started

2012

Primary outcome

Total to HDL Cholesterol Ratio

Coronary Heart Disease

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01428193TERMINATED
Sponsor

University of Virginia

Enrollment

4

Started

2006

Primary outcome

Slope of the Percent Change in Luteinizing Hormone (LH) Pulses as a Function of Day 7 Progesterone Level

Polycystic Ovary SyndromeHyperandrogenism

Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

NCT00719537TERMINATED
Sponsor

John Uckele

Enrollment

3

Started

2008

Primary outcome

Incidence of Preeclampsia

Preeclampsia

Low Molecular Weight Heparin in Recurrent Implantation Failure

NCT00750451COMPLETED
Sponsor

V.K.V. American Hospital, Istanbul

Started

2006

Primary outcome

Ongoing pregnancy beyond the 20th gestational week rate

InfertilityFertilization in VitroRecurrent Implantation Failure

Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer

Sponsor

Institute of Cancer Research, United Kingdom

Started

2002

Breast CancerHot FlashesMenopausal SymptomsOsteoporosis

Progesterone as Luteal Support in Frozen IVF Natural Cycles

NCT04725864Phase 4UNKNOWN
Sponsor

Vastra Gotaland Region

Enrollment

1,800

Started

2021

Primary outcome

Number of participants with live birth

InfertilityEmbryo Transfer

the Effects of GnRHa Add up to Routine Luteal Phase Support on Frozen Embryo Implantation in Frozen Embryo Transfer .

NCT02655146Phase 4UNKNOWN
Sponsor

Chong Qing Reproducive and Genetic Institute

Enrollment

700

Started

2015

Primary outcome

implantation rate

Infertility

Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer

NCT03120715Phase 4UNKNOWN
Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

342

Started

2016

Primary outcome

Clinical pregnancy rate

Infertility

Estradiol and Progesterone Levels Following Frozen Embryo Transfer

NCT04997525Phase 4COMPLETED
Sponsor

Copenhagen University Hospital at Herlev

Enrollment

305

Started

2021

Primary outcome

Serum estradiol

Infertility

Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.

NCT02032797Phase 4COMPLETED
Sponsor

Universitair Ziekenhuis Brussel

Enrollment

300

Started

2012

Primary outcome

clinical pregnancy rate

CryopreservationEmbryo ImplantationProgesteron

Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone

NCT01940653Phase 4COMPLETED
Sponsor

Universitair Ziekenhuis Brussel

Enrollment

300

Started

2012

Primary outcome

clinical pregnancy rate

Progesterone Supplementation

Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies

NCT01643980Phase 4COMPLETED
Sponsor

Dra.Cristina Martinez Payo

Enrollment

254

Started

2012

Primary outcome

Proportion of spontaneous preterm birth before 34 weeks of gestation

Early Onset of Delivery Before 37 Weeks

Preterm Delivery Prevention in Twins With Progesterone

NCT01927029Phase 4UNKNOWN
Sponsor

Universidad del Desarrollo

Enrollment

213

Started

2013

Primary outcome

Preterm delivery <34 weeks

Pregnancies

MENOPUR® Versus FOLLISTIM®

NCT00802360Phase 4COMPLETED
Sponsor

Ferring Pharmaceuticals

Enrollment

173

Started

2008

Primary outcome

Percentage of Participants With Ongoing Pregnancy at Week 8

Infertility

A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia

NCT01074892Phase 4COMPLETED
Sponsor

University Hospital of North Norway

Enrollment

170

Started

2005

Primary outcome

Regression of hyperplasia related to treatment arm after 6 months of therapy

Endometrial Hyperplasia

Threatened Preterm Labour: Vaginal Progesterone Versus Nifedipine

NCT07649668Phase 4COMPLETED
Sponsor

Dr Mudassar Saeed Pansota

Enrollment

160

Started

2025

Primary outcome

Percentage of efficacy

Preterm Labor

Luteal Support in Frozen-Thawed Embryo Transfer Cycles

NCT03948022Phase 4COMPLETED
Sponsor

Centrum Clinic IVF Center

Enrollment

151

Started

2021

Primary outcome

ongoing pregnancy rate

Implantation; PlacentaPregnancy LossFrozen EmbryoLuteal SupportLuteal Phase DefectAssisted Reproduction

Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth

NCT02970552Phase 4COMPLETED
Sponsor

University of North Carolina, Chapel Hill

Enrollment

140

Started

2017

Primary outcome

Adequate Adherence to Study Product

PreTerm Birth

Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles

NCT04124913Phase 4UNKNOWN
Sponsor

Memorial Sisli Hospital, Istanbul

Enrollment

140

Started

2019

Primary outcome

Ongoing pregnancy rate

Infertility, FemaleInfertility, MaleEmbryo TransferFertilization in VitroDrug EffectReproductive Techniques, AssistedProgesteroneDydrogesterone

Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

NCT01225835Phase 4COMPLETED
Sponsor

Ferring Pharmaceuticals

Enrollment

124

Started

2010

Primary outcome

Serum Progesterone (P4) Level in the Morning of the Day of Human Chorionic Gonadotrophin (hCG) Administration

Infertility

The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer

NCT04507022Phase 4COMPLETED
Sponsor

Rahem Fertility Center

Enrollment

112

Started

2020

Primary outcome

Ongoing Pregnancy Rate

InfertilityInfertility, FemaleInfertility, Male

Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain

NCT01056042Phase 4COMPLETED
Sponsor

Prince of Songkla University

Enrollment

112

Started

2007

Primary outcome

Patients' satisfaction with the treatment

Endometriosis

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277Phase 4RECRUITING
Sponsor

University of North Carolina, Chapel Hill

Enrollment

103

Started

2022

Primary outcome

Changes in Striatal Activation Between Groups during the MID task

DepressionPsychosisAnhedonia

Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies

NCT04748562Phase 4COMPLETED
Sponsor

Ain Shams University

Enrollment

100

Started

2020

Primary outcome

Preterm labor

Twin Pregnancy With Antenatal Problem

The Luteal Phase After GnRHa Trigger - a Proof of Concept Study

NCT01504139Phase 4COMPLETED
Sponsor

Regionshospitalet Viborg, Skive

Enrollment

93

Started

2012

Primary outcome

Levels of progesterone in the mid-luteal phase.

Progesterone LevelsInfertility

Estrogen Supplementation and Bone Health in Women With CF

NCT05704036Phase 4RECRUITING
Sponsor

Johns Hopkins University

Enrollment

75

Started

2023

Primary outcome

Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA)

Cystic FibrosisHypoestrogenism

Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

NCT01353846Phase 4UNKNOWN
Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Enrollment

70

Started

2011

Primary outcome

Preparation and treatment for Assisted Human Reproduction procedures and in the case opf pregnancy, follow up.

Infertility

Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

NCT03498313Phase 4COMPLETED
Sponsor

University of Illinois at Chicago

Enrollment

60

Started

2018

Primary outcome

Cyclical Change in Suicidal Ideation (SI) Severity

Suicidal Ideation

Endometrial Shedding Prior to Ovulation Induction Pilot Study

NCT02340013Phase 4COMPLETED
Sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Enrollment

50

Started

2013

Primary outcome

Composite measure of study feasibility

Infertility

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

NCT01148420Phase 4COMPLETED
Sponsor

Women's Health Care Clinic, Torrance, California

Enrollment

48

Started

2009

Primary outcome

Cessation of Bleeding Within 5 Days

Dysfunctional Uterine Bleeding

Adjunctive Vaginal Progesterone in Management of Preterm Labor

NCT05997563Phase 4UNKNOWN
Sponsor

Chulalongkorn University

Enrollment

48

Started

2023

Primary outcome

latency period

Preterm Labor

"Stair Step Study"

NCT03309176Phase 4COMPLETED
Sponsor

Radboud University Medical Center

Enrollment

42

Started

2016

Primary outcome

Ongoing pregnancy rate per cycle

Ovulation Disorder

Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure

NCT00732693Phase 4COMPLETED
Sponsor

University of Edinburgh

Enrollment

42

Started

2002

Primary outcome

Change in 24 hour ambulatory blood pressure

Premature Ovarian Failure

Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)

NCT00954811Phase 4UNKNOWN
Sponsor

Universitair Ziekenhuis Brussel

Enrollment

40

Started

2005

Primary outcome

pregnancy occurrence, pregnancy loss

PregnancyPregnancy Loss

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656Phase 4COMPLETED
Sponsor

University of North Carolina, Chapel Hill

Enrollment

40

Started

2022

Primary outcome

Mean IDAS Ill Temper Scale Score Over Time

MenopauseIrritable Mood

Endometrial Receptivity After GnRH Agonist Triggering

NCT01500863Phase 4COMPLETED
Sponsor

IVI Madrid

Enrollment

35

Started

2011

Primary outcome

endometrial receptivity gene expression profile

Ovarian Hyperstimulation Syndrome

Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor

NCT01286246Phase 4TERMINATED
Sponsor

University of Calgary

Enrollment

34

Started

2011

Primary outcome

Gestational age at birth

Obstetric Labor, Premature

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847Phase 4COMPLETED
Sponsor

University of North Carolina, Chapel Hill

Enrollment

30

Started

2016

Primary outcome

Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score

Suicidal Ideation

Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women

NCT00755963Phase 4COMPLETED
Sponsor

Medical University of Vienna

Enrollment

30

Started

2009

Primary outcome

Serotonin-1A receptor binding potential

Hormone Replacement

Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

NCT03677336Phase 4COMPLETED
Sponsor

CRG UZ Brussel

Enrollment

30

Started

2019

Primary outcome

Molecular endometrial level using illumina RNA-seq

Infertility, FemaleInfertilityGenital Diseases, MaleGenital Diseases, FemaleProgesteroneDydrogesteroneHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of DrugsProgestins

Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion

NCT01809639Phase 4COMPLETED
Sponsor

Wake Forest University Health Sciences

Enrollment

25

Started

2013

Primary outcome

Time (in Days) That a Patient Reports Symptoms From Their Concussion.

Concussion

Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs

NCT01465373Phase 4COMPLETED
Sponsor

Fertility Centers of Illinois

Enrollment

10

Started

2010

Primary outcome

Clinical pregnancy rate of micronized vaginal progesterone (Endometrin, Ferring Pharmaceuticals) compared to intramuscular progesterone supplementation for luteal phase support after IVF-ET from previously vitrified donor eggs

Infertility

Progesterone and Resting Energy Expenditure

NCT04140968Phase 4TERMINATED
Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

2

Started

2019

Primary outcome

Mean change in resting energy expenditure

MenopauseProgesteroneWeight Gain

Heart and Estrogen-Progestin Replacement Study (HERS)

NCT00319566Phase 3COMPLETED
Sponsor

University of California, San Francisco

Enrollment

2,430

Started

1992

Primary outcome

Myocardial Infarction

Coronary Heart Disease

Chinese Herbal Medicine (New "Shoutai Wan") and/or Oral Progesterone Intervention Trial for Threatened Miscarriage

NCT02633878Phase 3COMPLETED
Sponsor

Heilongjiang University of Chinese Medicine

Enrollment

1,656

Started

2017

Primary outcome

Live birth

Threatened Miscarriage

Progesterone for the Treatment of Traumatic Brain Injury III

NCT00822900Phase 3TERMINATED
Sponsor

David Wright

Enrollment

882

Started

2010

Primary outcome

Favorable Outcome as Determined by the Glasgow Outcome Scale-Extended (GOSE)

Traumatic Brain Injury

Progesterone Supplementation on Women Having Low Progesterone Levels on Transfer Day

NCT04897269Phase 3UNKNOWN
Sponsor

Tu Du Hospital

Enrollment

824

Started

2021

Primary outcome

Ongoing pregnancy rate

Assisted Reproductive Technology

17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor

NCT00809939Phase 3UNKNOWN
Sponsor

Meir Medical Center

Enrollment

800

Started

2010

Primary outcome

efficacy

Pregnancy

Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer

NCT01608451Phase 3TERMINATED
Sponsor

Tata Memorial Hospital

Enrollment

800

Started

2007

Primary outcome

Disease-free survival

Locally Advanced Breast Cancer and Large Operable Breast Cancer

Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)

NCT00828191Phase 3COMPLETED
Sponsor

IBSA Institut Biochimique SA

Enrollment

800

Started

2008

Primary outcome

Ongoing Pregnancy Rate

In Vitro Fertilization

Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

NCT00099164Phase 3COMPLETED
Sponsor

The George Washington University Biostatistics Center

Enrollment

795

Started

2004

Primary outcome

Delivery prior to 35 weeks 0 days gestation

Preterm BirthPregnancyMultifetal

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

NCT04414761Phase 3COMPLETED
Sponsor

ShangHai Ji Ai Genetics & IVF Institute

Enrollment

784

Started

2020

Primary outcome

live birth rate

IVFGnRH AntagonistPPOS

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

NCT06150703Phase 3RECRUITING
Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

652

Started

2024

Primary outcome

Live birth, defined as the presence of a live birth after 22 weeks' gestation. Twin pregnancies will be counted as a single birth.

In Vitro FertilizationICSI Intracytoplasmic Spermatozoid Injection

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

NCT07831902Phase 3RECRUITING
Sponsor

University College, London

Enrollment

600

Started

2026

Primary outcome

Recurrence free survival (RFS)

Endometrial CancerUterine Neoplasms

Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy

NCT05586724Phase 3RECRUITING
Sponsor

Angelica Lindén Hirschberg

Enrollment

520

Started

2022

Primary outcome

Mammographic breast density

Menopausal Symptoms

PREGNANT Short Cervix Trial

NCT00615550Phase 3COMPLETED
Sponsor

Juniper Pharmaceuticals, Inc.

Enrollment

465

Started

2008

Primary outcome

Number of Participants With Birth <=32 6/7 Weeks Gestation.

Preterm DeliveryShort CervixShort Uterine Cervical Length

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

NCT00416429Phase 3COMPLETED
Sponsor

Centre Leon Berard

Enrollment

456

Primary outcome

Overall survival

Kidney Cancer

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

NCT00291369Phase 3COMPLETED
Sponsor

Centre Leon Berard

Enrollment

456

Started

1999

Primary outcome

Overall survival

Metastatic Renal Cell Carcinoma

Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures

NCT03565211Phase 3COMPLETED
Sponsor

Ferring Pharmaceuticals

Enrollment

352

Started

2018

Primary outcome

Cumulative Rate of Spontaneous Abortions Occurring on or Before 12 Weeks Post-oocyte Retrieval

Progesterone Supplementation in Women Undergoing ART

Progesterone-modified Natural Cycle for FET

NCT06644794Phase 3RECRUITING
Sponsor

Shandong University of Traditional Chinese Medicine

Enrollment

336

Started

2025

Primary outcome

Live birth

Infertility, Female

Nintedanib for Improving Reproductive Outcomes in Adenomyosis

NCT07162961Phase 3NOT_YET_RECRUITING
Sponsor

Sun Yat-sen University

Enrollment

328

Started

2025

Primary outcome

live birth rate

Adenomyosis of Uterus

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

NCT00002920Phase 3COMPLETED
Sponsor

SWOG Cancer Research Network

Enrollment

313

Started

1997

Primary outcome

Endometrial pathologic diagnosis

Breast CancerEndometrial Cancer

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

NCT03097120Phase 3COMPLETED
Sponsor

Wake Forest University Health Sciences

Enrollment

309

Started

1995

Primary outcome

mean minimal coronary-artery diameter

Heart Disease

Progesterone vs Placebo Therapy for Women With Epilepsy

NCT00029536Phase 3COMPLETED
Sponsor

Beth Israel Deaconess Medical Center

Enrollment

294

Started

2000

Primary outcome

Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency

Epilepsy

Natural Progesterone and Preterm Birth in Twins

NCT00480402Phase 3COMPLETED
Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Enrollment

290

Started

2006

Preterm Birth

Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET

NCT03071172Phase 3UNKNOWN
Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.

Enrollment

252

Started

2017

Primary outcome

The total number of oocytes obtained during the start-up period

Ovarian Hyperstimulation Syndrome

Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial

NCT00422526Phase 3COMPLETED
Sponsor

King's College Hospital NHS Trust

Enrollment

250

Started

2003

Primary outcome

Spontaneous delivery before 34 completed weeks (238 days) of gestation.

Preterm BirthPregnancy Trimester, Second

Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.

NCT02118051Phase 3COMPLETED
Sponsor

Instituto de Investigacion Sanitaria La Fe

Enrollment

234

Started

2013

Primary outcome

Rate of evolutionary gestation in each cycle

Infertility

Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor

NCT02989519Phase 3COMPLETED
Sponsor

Sanpasitthiprasong Hospital

Enrollment

231

Started

2015

Primary outcome

preterm delivery before 34 and 37 weeks

Preterm Delivery

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

NCT00030914Phase 3COMPLETED
Sponsor

Alliance for Clinical Trials in Oncology

Enrollment

227

Started

2002

Primary outcome

Compare the efficacy of the three regimens

Hot Flashes

Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone

NCT07613528Phase 3NOT_YET_RECRUITING
Sponsor

University Hospital, Montpellier

Enrollment

214

Started

2027

Primary outcome

Live birth rate

PregnancyProgesterone SupplementationLow Serum Progesterone

Somatropin Treatment to Final Height in Turner Syndrome

NCT00191113Phase 3COMPLETED
Sponsor

Eli Lilly and Company

Enrollment

154

Started

1989

Primary outcome

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population

Turner Syndrome

Role of Triptorelin 0.1 mg as a Luteal Phase Support in Assisted Reproductive Technique After Embryo Transfer : a Randomized Controlled Trial

NCT04087408Phase 3UNKNOWN
Sponsor

Moustafa Mohammed Abouelea

Enrollment

150

Started

2020

Primary outcome

Ongoing clinical pregnancy rate

Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles

Comparison Between Vaginal Pessary and Progestogen in Twin Pregnancy With Short Cervical Length

NCT04342585Phase 3COMPLETED
Sponsor

National University of Malaysia

Enrollment

142

Started

2019

Primary outcome

Spontaneous preterm birth

Preterm Birth

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

NCT04537078Phase 3COMPLETED
Sponsor

El Shatby University Hospital for Obstetrics and Gynecology

Enrollment

90

Started

2020

Primary outcome

the Number of M2 Oocytes Retrieved

Infertility, Female

Study of Progesterone in Treatment of Vasomotor Symptoms

NCT03202186Phase 3TERMINATED
Sponsor

BHR Pharma, LLC

Enrollment

55

Started

2017

Primary outcome

Frequency of moderate to severe vasomotor symptoms at 12 weeks

Menopause Related Conditions

Oral Progesterone for Prevention of Preterm Birth

NCT01180296Phase 3COMPLETED
Sponsor

Fetal Medicine Foundation

Enrollment

36

Started

2006

Primary outcome

Rate of Recurrent Preterm Birth

Preterm Birth

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea

NCT02019589Phase 3TERMINATED
Sponsor

TherapeuticsMD

Enrollment

6

Started

2014

Primary outcome

• The proportion of subjects at Cycle 3 Day 24 ± 1 day on active treatment compared to placebo with complete secretory activity on endometrial biopsy.

Secondary Amenorrhea

Progesterone in Threatened Abortion

NCT02950935Phase 3TERMINATED
Sponsor

IBSA Institut Biochimique SA

Enrollment

4

Started

2017

Primary outcome

Ongoing pregnancy rate at 12 weeks of gestation

Threatened Abortion in First Trimester

Postmenopausal Hormone Therapy in Unstable Angina

NCT00000601Phase 3COMPLETED
Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Started

1995

Angina, UnstableCardiovascular DiseasesCoronary DiseaseHeart DiseasesPostmenopause

Estrogen and Graft Atherosclerosis Research Trial (EAGER)

NCT00000605Phase 3COMPLETED
Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Started

1996

Cardiovascular DiseasesCoronary ArteriosclerosisCoronary DiseaseHeart DiseasesMyocardial IschemiaPostmenopause

Alzheimer's Disease Prevention Trial

NCT00000176Phase 3COMPLETED
Sponsor

National Institute on Aging (NIA)

Alzheimer DiseaseMemory Disorders

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

NCT00026286Phase 3COMPLETED
Sponsor

Eastern Cooperative Oncology Group

Started

2000

Breast CancerHot FlashesMenopausal Symptoms

Cervical Pessary vs Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial

NCT02470676Phase 2/3UNKNOWN
Sponsor

Hillel Yaffe Medical Center

Enrollment

430

Started

2015

Primary outcome

preterm birth before 34 weeks of gestation rate in singleton pregnancies

Preterm BirthShort Cervix

17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

NCT00163020Phase 2/3COMPLETED
Sponsor

Obstetrix Medical Group

Enrollment

321

Started

2004

Primary outcome

Newborn Respiratory Distress Syndrome (RDS)

Preterm Birth

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

NCT03463252Phase 2/3RECRUITING
Sponsor

West China Second University Hospital

Enrollment

224

Started

2018

Primary outcome

Pathologic Response

Endometrial CancerAtypical Endometrial Hyperplasia

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

NCT05565573Phase 2/3UNKNOWN
Sponsor

Hua Li

Enrollment

148

Started

2022

Primary outcome

Complete response rate

Fertility Sparing

Progesterone Treatment for Cocaine-dependent Women: A Pilot Study

NCT00632099Phase 2/3COMPLETED
Sponsor

New York State Psychiatric Institute

Enrollment

21

Started

2008

Primary outcome

Cocaine Abstinence Based on Urine Toxicology Results

Cocaine Dependence

Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

NCT00946088Phase 2/3TERMINATED
Sponsor

Stanford University

Enrollment

7

Started

2009

Primary outcome

Reduction in Delivery Rate Prior to 37 Weeks Gestation

Pregnancy Complications

A Randomized Controlled Study of Prolonging the Time of Progesterone Supplementation to Improve the Pregnancy Outcome of Single Day 6 Blastocyst Transfer of Freeze-thaw Cycle

NCT04938011Phase 2UNKNOWN
Sponsor

Nanjing University

Enrollment

900

Started

2021

Primary outcome

Embryo implantation rate

Infertility

Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial

NCT02145767Phase 2COMPLETED
Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Enrollment

850

Started

2014

Primary outcome

Miscarriage

MiscarriagePreterm Birth

Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles

NCT02677259Phase 2UNKNOWN
Sponsor

One Fertility

Enrollment

506

Started

2016

Primary outcome

Clinical Pregnancy

IVF

Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis

NCT00437658Phase 2COMPLETED
Sponsor

AbbVie

Enrollment

252

Started

2006

Primary outcome

Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24

Endometriosis

The Vaginal Progesterone and Cerclage

NCT02846909Phase 2COMPLETED
Sponsor

Assiut University

Enrollment

242

Started

2017

Primary outcome

The frequency of spontaneous abortion before 28 weeks

Abortion

Rescue Progesterone Supplementation During Frozen Embryo Transfer

NCT05555121Phase 2SUSPENDED
Sponsor

Clinique Ovo

Enrollment

150

Started

2022

Primary outcome

Evaluate the ongoing pregnancy rate

Fertility IssuesEmbryo ImplantationFrozen Embryo Transfer

Impact of Progesterone on Stress Reactivity and Cannabis Use

NCT03729869Phase 2COMPLETED
Sponsor

Medical University of South Carolina

Enrollment

148

Started

2019

Primary outcome

Cannabis Craving

Cannabis Use

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

NCT07436793Phase 2RECRUITING
Sponsor

New Mexico Cancer Research Alliance

Enrollment

140

Started

2026

Primary outcome

Tissue response to progestin therapy

Endometrial Endometrioid AdenocarcinomaEndometrial Hyperplasia

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

NCT00739830Phase 2COMPLETED
Sponsor

Merck Sharp & Dohme LLC

Enrollment

130

Started

2008

Primary outcome

Progression-free survival (PFS)

Endometrial Cancer

Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone

NCT00152438Phase 2UNKNOWN
Sponsor

University of British Columbia

Enrollment

125

Started

2005

Primary outcome

Vasomotor symptoms prospectively recorded in the final month of therapy by therapy assignment, with pre-therapy baseline vasomotor symptoms as a covariate.

Menopause

Randomized Trial of Maternal Progesterone Therapy

NCT02133573Phase 2COMPLETED
Sponsor

Children's Hospital of Philadelphia

Enrollment

102

Started

2014

Primary outcome

Motor Scale of the Bayley Scales of Infant and Toddler Development-III

Congenital Heart DiseasePeriventricular LeucomalaciaBrain DevelopmentCardiac SurgeryNeurodevelopmental DisabilityFetal Neuroprotection

Research Investigation of Soy and Estrogen

NCT00997893Phase 2COMPLETED
Sponsor

University of Illinois at Chicago

Enrollment

96

Started

2009

Primary outcome

Change in STAI-6 Score

MenopauseHot Flashes

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

NCT05675787Phase 2UNKNOWN
Sponsor

Peking University People's Hospital

Enrollment

82

Started

2023

Primary outcome

Pathological cumulative complete response rate;

Atypical Endometrial HyperplasiaEndometrial Carcinoma Stage I

Efficacy Study of Progesterone Tablet in Post-menopausal Women

NCT02841137Phase 2COMPLETED
Sponsor

IBSA Institut Biochimique SA

Enrollment

80

Started

2016

Primary outcome

endometrial thickness change towards baseline (mm)

Menopause

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

NCT02335203Phase 2UNKNOWN
Sponsor

Women and Infants Hospital of Rhode Island

Enrollment

76

Started

2015

Primary outcome

Change in glandular cellularity

Grade 1 Endometrial Endometrioid AdenocarcinomaGrade 2 Endometrial Endometrioid AdenocarcinomaComplex Atypical Endometrial Hyperplasia

The Role of Hormones in Postpartum Mood Disorders

NCT00001481Phase 2COMPLETED
Sponsor

National Institute of Mental Health (NIMH)

Enrollment

74

Started

1996

Primary outcome

Edinburgh Postnatal Depression Scale (EPDS) Mean Total Score

Postpartum Depression

Cerclage and Progesterone for Twin Pregnancies

NCT07319715Phase 2COMPLETED
Sponsor

Benha University

Enrollment

59

Started

2023

Primary outcome

Success Rate of Treatment Regimens in Preventing Preterm Birth and/or Improving Pregnancy Duration

Twin Pregnancy With Antenatal Problem

Feasibility Study Into the Contraceptive Effect of Estetrol

NCT00563472Phase 2COMPLETED
Sponsor

Pantarhei Bioscience

Enrollment

52

Started

2007

Primary outcome

ovulation inhibition

Healthy

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122Phase 2COMPLETED
Sponsor

Indiana University

Enrollment

30

Started

2007

Primary outcome

Clinical Benefit Rate (CR + PR + SD > 6 Months).

Estrogen Receptor-negative Breast CancerProgesterone Receptor-negative Breast CancerRecurrent Breast CancerStage IV Breast Cancer

Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls

NCT00005108Phase 2COMPLETED
Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment

25

Started

2000

AtherosclerosisHealthyVascular Disease

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320Phase 2COMPLETED
Sponsor

University of North Carolina, Chapel Hill

Enrollment

23

Started

2020

Primary outcome

Mean Threat Processing Bias During Visual Dot-probe Paradigm Over Time

Perinatal DepressionPost Partum DepressionDepression, PostpartumDepression

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

NCT03212170Phase 2COMPLETED
Sponsor

University of Wisconsin, Madison

Enrollment

21

Started

2017

Primary outcome

Correlation Coefficient Between FFNP Uptake and Allred Score

Invasive Breast Cancer

Progesterone Treatment in Female Smokers - 12

NCT00000295Phase 2COMPLETED
Sponsor

National Institute on Drug Abuse (NIDA)

Enrollment

0

Started

1999

Primary outcome

Behavioral

Tobacco Use Disorder

Progesterone Treatment of Blunt Traumatic Brain Injury

NCT00048646Phase 1/2COMPLETED
Sponsor

David Wright

Enrollment

100

Started

2002

Primary outcome

neurological outcome

Traumatic Brain Injury

Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration

NCT01057511Phase 1/2COMPLETED
Sponsor

Peking Union Medical College Hospital

Enrollment

51

Started

2009

Primary outcome

Primary endpoint: progesterone level in endometrium and in serum

Postmenopausal Endometrium

Male Hormonal Contraceptive Development-ACY-5

NCT00161447Phase 1/2COMPLETED
Sponsor

University of Washington

Enrollment

43

Started

2004

Primary outcome

The primary biological end points in this trial will be suppression of spermatogenesis and gonadotropins while monitoring for any adverse changes in lipid metabolism, sexual side effects or in general health

Contraception

Blocking Mifepristone Action With Progesterone

NCT03774745Phase 1/2TERMINATED
Sponsor

University of California, Davis

Enrollment

12

Started

2019

Primary outcome

Continuing Pregnancy Based on Ultrasound Examination

Pregnancy, Unwanted

Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support

NCT05969795Phase 1RECRUITING
Sponsor

ART Fertility Clinics LLC

Enrollment

342

Started

2023

Primary outcome

Implantation rate

Pregnancy RelatedInfertility, Female

Progesterone and Aminophylline for the Prevention of Preterm Labour

NCT03152942Phase 1UNKNOWN
Sponsor

St Stephens Aids Trust

Enrollment

70

Started

2017

Primary outcome

To assess number of women at high risk of Preterm Labour (PTL) withdraw from the combination therapy of Progesterone (P4) and aminophylline due to side effects, in comparison to P4 alone.

Premature Obstetric Labor

Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal Route

NCT05125627Phase 1COMPLETED
Sponsor

Joint Stock Company "Farmak"

Enrollment

66

Started

2019

Primary outcome

Cmax

Pharmacokinetics

Effect of Progesterone on Smoking Behavior in Male and Female Smokers

NCT00271206Phase 1COMPLETED
Sponsor

Yale University

Enrollment

65

Started

2004

Primary outcome

Smoking topography; measured by carbon monoxide levels and self-report at Day 4

Tobacco Use Disorder

Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert

NCT06668896Phase 1NOT_YET_RECRUITING
Sponsor

Daré Bioscience, Inc.

Enrollment

60

Started

2026

Primary outcome

Systemic pharmacokinetics of progesterone, Concentration over 24 hours

Pre Term Birth

Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues

NCT00585520Phase 1COMPLETED
Sponsor

Yale University

Enrollment

60

Started

2007

Primary outcome

HPA responses to stress

Cocaine Dependence

A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women

NCT02092571Phase 1COMPLETED
Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Enrollment

56

Started

2014

Primary outcome

baseline-adjusted AUCt

Pharmacokinetics

Progesterone Microspheres Pharmacokinetic - Pharmacodynamic (PK-PD) Study

NCT01176175Phase 1COMPLETED
Sponsor

Productos Científicos S. A. de C. V.

Enrollment

48

Started

2010

Primary outcome

Endometrial dating through histopathologic criteria.

Infertility

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

NCT02272647Phase 1COMPLETED
Sponsor

Mayo Clinic

Enrollment

47

Started

2014

Primary outcome

Logarithm of the ratio of the normalized growth hormone secretion rate over the first 10 hr.

Healthy

Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls

NCT01773772Phase 1COMPLETED
Sponsor

University of Virginia

Enrollment

14

Started

2005

Primary outcome

LH pulse frequency (number of LH pulses per hour)

Female Puberty

Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)

NCT01602679Phase 1TERMINATED
Sponsor

University of Virginia

Enrollment

12

Started

2012

Primary outcome

Change in Number of LH Pulses Per Hour

Female Reproductive Physiology

Pharmacokinetics of Progesterone in Pregnancy

NCT03340701Phase 1COMPLETED
Sponsor

Thomas Jefferson University

Enrollment

6

Started

2017

Primary outcome

Pharmacokinetic model

Progesterone

Effect of Progesterone Therapy on Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

NCT04426487Early Phase 1UNKNOWN
Sponsor

Minia University

Enrollment

200

Started

2020

Primary outcome

Number of participants suffering neuronal infarction

Traumatic Brain Injury

Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer

NCT04046185Early Phase 1UNKNOWN
Sponsor

Shanghai First Maternity and Infant Hospital

Enrollment

60

Started

2019

Primary outcome

Pathologic complete remission rate of endometrial curettage tissues

Endometrial Cancer Stage I

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

NCT03018249Early Phase 1COMPLETED
Sponsor

National Cancer Institute (NCI)

Enrollment

50

Started

2017

Primary outcome

Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score)

FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaFIGO Grade 3 Endometrial Endometrioid Adenocarcinoma

Clinical Study on Endometrial Receptivity

NCT03687021Early Phase 1UNKNOWN
Sponsor

Peking Union Medical College Hospital

Enrollment

35

Started

2018

Primary outcome

endometrial receptivity measured by pathology

Endometrial Receptivity;RNA; Progesterone

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099Early Phase 1UNKNOWN
Sponsor

University of Virginia

Enrollment

10

Started

2022

Primary outcome

Change in mean FSH concentration with progesterone administration

PCOSPolycystic Ovary Syndrome

Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone

NCT06616077Early Phase 1COMPLETED
Sponsor

Reproductive Health Research Insritute, Chile

Enrollment

9

Started

2022

Primary outcome

Endometrial Gene Expression Profile

Endometrial Endocrine RegulationProgesterone Supplementation in Women After Mifepristone

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer